Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus

Ahn, Sung Soo; Jung, Seung Min; Yoo, Juyoung; Lee, Sang Won; Song, Jason Jungsik; Park, Yong Bum

doi:10.1007/s00296-019-04445-y

Cited by 34 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 Meanwhile, Ahn et al found no association between LN and Anti-Sm. 41 Anti-Sm was associated with consumed C3 (p<0.001), proteinuria (p=0.015), active urinary sediment (pus cell (p=0.032), red cell (p=0.034), and urinary cast (p=0.010), which indicates a strong significant association between anti-Sm and severity of LN and with disease duration (p=0.044). Emad et al also found similar findings.…”

Section: Discussionmentioning

confidence: 92%

“…However, it was not significantly correlated with anti-U1-RNP 11 Ahn et al stated that the anti-Sm antibody and the activity of the disease were significantly correlated. 41 In contrast, Agarwal et al found that there was no association between different anti-ENA antibodies and disease activity score. 47 Our study had some limitations; it was a cross-sectional study, all of the patients held a unique Egyptian background, and study was conducted at certain point of time, so we cannot say, whether the association will persist over time and during transitional zone from juvenile to adulthood period.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity

Teama¹,

El-Mohamdy²,

Mahmoud³

et al. 2021

OARRR

View full text Add to dashboard Cite

This study was conducted to estimate the frequency of anti-nuclear antibodies (ANAs), anti-dsDNA, and anti-extractable nuclear antigen (ENA) antibodies in juvenile systemic lupus erythematosus (JSLE) patients and their association with different clinical manifestations and disease activity. Patients and Methods: A cross-sectional study that includes 100 JSLE patients from Ain Shams University Hospital was conducted. All subjects underwent history taking, clinical examination, assessment of disease activity based on the SLE disease activity index (SLEDAI), laboratory investigations, and tests for autoantibodies, namely ANA, anti-dsDNA, and anti-ENA antibodies, including anti-Ro (SSA), anti-La (SSB), anti-Smith (Sm), and anti-U1-ribonucleoprotein (U1-RNP). Results: The most common clinical features were polyarthralgia (71%), haematological manifestations (65%), malar rash (54%), and nephritis (51%), respectively. All patients had positive ANA (100%), while anti-dsDNA frequency was 83%. The most common anti-ENA antibodies were anti-RNP (41%), anti-Sm (31%), anti-SSA (27%), and anti-SSB (20%), respectively. Anti-RNP had a clinical association with oral ulcer, Raynaud' phenomena, haematological, neuropsychiatric and thromboembolic manifestations. Meanwhile, anti-Sm had a significant association with serositis, mucocutaneous, constitutional, and neuropsychiatric manifestations. Anti-SSA was associated with mucocutaneous, musculoskeletal, Raynaud' phenomena, renal, haematological and cardiac manifestations, while anti-SSB was significantly associated with malar rash, serositis, thromboembolic, musculoskeletal, and neuropsychiatric manifestations. Concerning SLEADI score, anti-dsDNA antibody was significantly associated with moderate disease activity score (p=0.032) while anti-SSA significantly associated with high disease activity (p=0.045). Both anti-SSB and anti-Sm were significantly associated with both moderate and high disease activities, meanwhile anti-U1-RNP was associated with moderate disease activity (p=0.014). Conclusion:Anti-dsDNA and anti-ENAs antibodies were frequently found in JSLE patients (83%, 63%), respectively. They were significantly associated with variable clinical manifestations and could be used as predictors for assessment of disease activity.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 95%

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity

Teama¹,

El-Mohamdy²,

Mahmoud³

et al. 2021

OARRR

View full text Add to dashboard Cite

show abstract

“…Anti-Smith (anti-Sm) antibodies are a highly specific autoantibody in SLE, directly against seven Smith proteins that constitute the small nuclear ribonucleoprotein particles [21,22]. Besides acting as a SLE classification criterion, anti-Sm antibody has been found to be related with specific subsets of system involvements [23] and disease activity [24]. In terms of skin manifestation, previous research revealed that anti-Sm antibody was associated with photosensitivity, malar rash, and discoid rash [25,26].…”

Section: Discussionmentioning

confidence: 99%

Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus

Xiang

Luo

et al. 2021

Arthritis Res Ther

View full text Add to dashboard Cite

Background Scarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLE patients. Methods SLE patients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring alopecia was defined according to SLICC/ACR-DI which was collected during follow-up visits or via self-reported questionnaires. We collected demographic characteristics, common comorbidities, autoantibody profiles, disease activity status, major organ involvements, and treatment strategies of these patients at registry. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for scarring alopecia. Results We recruited 4792 SLE patients, and 374 (7.80%) patients had scarring alopecia. Mucocutaneous lesions (OR 2.062, p < 0.001), high SLICC/ACR-DI (OR 1.409, p < 0.001), and positive anti-Sm (OR 1.374, p = 0.029) were risk factors for scarring alopecia, while renal (OR 0.714, p = 0.028) and cardio-respiratory involvements (OR 0.347, p = 0.044), and immunosuppressant treatment (OR 0.675, p < 0.001) were significantly negative associated with it. Conclusions The prevalence of scarring alopecia in SLE patients is 7.80%. Active treatment strategies should be adopted to prevent scarring alopecia occurring.

show abstract

“…At present, there are few related studies on ANA antibody pro le and speci c organ involvement in SLE/LN: Anti-Sm antibodies were associated with neurologic disorder and cardiovascular disease, besides, anti-Sm antibody was also associated with disease activity in SLE patients. [14][15][16] It had been reported that anti-SSA antibodies with skin involvement and sicca symptoms; [17] SLE patients with anti-SSA antibodies revealed higher frequencies of cutaneous vasculitis, severe mitral valve regurgitation and musculoskeletal involvement. [18,19] Anti-RNP antibodies are more prevalent in patients with Raynaud's phenomenon and are associated with renal involvement; [20,21] Another research reported that the combination of anti-RNP/Sm and LA was associated with thrombosis in SLE.…”

Section: Discussionmentioning

confidence: 99%

Identification of Novel Classes for Patients With Lupus Nephritis Using Two-step Cluster Model

Huang¹,

Xie²,

Ding³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: To identify and reclassify the patients in the LN cohort, and to further analyze the prominent clinical features and clinical significance of each cluster of patients.Methods: This is a cross-sectional study of a cohort of 635 LN patients from the Rheumatology Department of Xiangya Hospital of Central South University. Demographic data, laboratory findings and clinical evaluation system include physician’s global assessment and the SLICC/ACR Damage Index were collected. Using two-step cluster analysis, patients with similar clinical property were identified and compared.Results: Among the 635 LN patients, 599 patients (94.3%) were female. The mean age of the patients were 33.8 ± 10.4 years. Three subgroups were identified by two-step cluster analysis. Cluster 1 included 130 (20.5%) patients, Cluster 2 included 132(20.8%) patients and Cluster 3 included 373 (58.7%) patients. Cluster 3 was the largest group of mild disease activity, patients in this cluster had lower white blood cells, neutrophils, lymphocytes and mean SDI scores compared to those in the other two clusters. Cluster 1 was the smallest group of severe damage, patients in this cluster had multiple positive auto-antibodies, higher SDI scores and lower complement level. Patients of cluster 2 had the highest levels of granulocytes, but the results of other laboratory tests were roughly between the cluster 1 and cluster 3.Conclusions: This study reclassified three groups of LN patients in a large cohort. Our research shows that the multiple positive ANA antibody may be related to the high SDI score of LN patients. Clinicians can identify patients at different stages through cluster analysis to better implement prognosis.

show abstract

Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus

Cited by 34 publications

References 17 publications

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity

Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus

Identification of Novel Classes for Patients With Lupus Nephritis Using Two-step Cluster Model

Contact Info

Product

Resources

About